Evidence map›Paper›PMID 35733228›Full record

Observational studyEuropean journal of medical research2022

Who is pausing immunosuppressive medication for COVID-19 vaccination? Results of an exploratory observational trial.

Dominik Schröder, Stephanie Heinemann, Gloria Heesen, Frank Klawonn, Marie Mikuteit, Jacqueline Niewolik, Sandra Steffens, Georg Behrens, Alexandra Jablonka, Frank Müller

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dominik Schröder *Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.
Stephanie Heinemann *Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.
Gloria HeesenDepartment of General Practice, University Medical Center Goettingen, Goettingen, Germany.
Frank KlawonnDepartment of Computer Science, Ostfalia University of Applied Sciences, Wolfenbuettel, Germany.
Marie MikuteitDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Jacqueline NiewolikDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Sandra SteffensDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Georg BehrensDepartment of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Alexandra Jablonka *German Center for Infection Research (DZIF), Partner Site Hannover, Braunschweig, Germany.
Frank Müller *Department of General Practice, University Medical Center Goettingen, Goettingen, Germany. frank.mueller@med.uni-goettingen.de.
Medizinische Hochschule Hannover · DEGerman Center for Infection Research · DEOstfalia University of Applied Sciences · DE

Funding

European Fund for Regional Development ZW7-85152953
6 · The paper itself

Abstract

backgroundThe influence of immunosuppressive therapy on immunogenicity after COVID-19 vaccination remains unclear. This study surveys patients who receive immunosuppressive therapy about whether or not they paused their immunosuppressive medication while receiving SARS-CoV-2 vaccination.

methodsIn this prospective observational study, immunosuppressed participants were asked by phone and email about their medication before and during vaccination and who-if anyone-advised them to pause their medication. In addition, a baseline paper-based questionnaire contributes general characteristics regarding age, gender, immunosuppressive medication(s) and the chronic disease(s) requiring immunosuppressive therapy.

resultsOf 207 surveyed participants, 59 persons (28.5%) paused their immunosuppressive medication before/during vaccination. Persons with rheumatic conditions and women were significantly more likely to pause immunosuppressive therapy than others. Over half of those who paused their medication reported receiving a recommendation from their specialist and 22.0% (13 of 59) decided to pause medication themselves without consulting a physician in advance.

conclusionsBesides lack of evidence, many immunosuppressed individuals and their treating physicians choose to pause medication before COVID-19 vaccination and accepting the risk of worsening their underlying disease.

trial registrationDRKS00023972, registered 12/30/2020.

Indexed as

COVID-19COVID-19 VaccinesFemaleHumansProspective StudiesSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19Drug adherenceDrug complianceImmunizationImmunogenicityImmunosuppressionSARS-CoV-2

Identifiers

PMID35733228
PMCPMC9214675
OpenAlexW4283367376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.